Fluorescent probes of alpha- and beta-adrenergic and opiate receptors: biochemical and histochemical evaluation.
Dansyl derivatives of the opiate antagonist naloxazone and the alpha-adrenergic blocking drug 2-[2',6'-dimethoxy)phenoxyethylamino]methyl-benzodioxan (WB-4101) were synthesized as potential in vivo fluorescent labels for opiate and alpha-adrenergic receptors, respectively. When assayed in vitro dansyl analogs display Ki-values for [3H]naloxone and [3H]WB-4101 binding of 8 nM and 80 nM, respectively. The same patterns of histofluorescence are observed in rat brain slices after the intravenous or intracerebroventricular injection of both dansyl drugs. The same patterns are also observed in dansyl-propranolol and 9-aminoacridine-propranolol (9-AAPN) treated animals as well as in untreated control rats. Accordingly, the observed fluorescence does not reflect the labeling of any receptor but is consistent with the distribution of lipofuscin, an endogenous fluorescent compound.
D000317:Adrenergic alpha-Antagonists / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D001921:Brain / Q000378:metabolism*; D003619:Dansyl Compounds / Q000494:pharmacology; D004146:Dioxanes / Q000378:metabolism; D005456:Fluorescent Dyes; D066298:In Vitro Techniques; D008297:Male; D008856:Microscopy, Fluorescence; D009270:Naloxone / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D011941:Receptors, Adrenergic / Q000378:metabolism*; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism*; D011943:Receptors, Adrenergic, beta / Q000378:metabolism*; D011957:Receptors, Opioid / Q000378:metabolism*; D013050:Spectrometry, Fluorescence
D000317:Adrenergic alpha-Antagonists; D003619:Dansyl Compounds; D004146:Dioxanes; D005456:Fluorescent Dyes; D011941:Receptors, Adrenergic; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D011957:Receptors, Opioid; D009270:Naloxone; C010654:(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane